SiteMap
- Home
- About Us
- Technology
- Pipeline
- Clinical Trials
- Newsroom
- Bellicum Appoints Baylor College of Medicine’s David M. Spencer as Chief Scientific Officer
- Bellicum Closes $20 Million Series B Financing
- Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients
- Bellicum Pharmaceuticals Awarded $5.7 Million by the Cancer Prevention and Research Institute of Texas
- Journal of Clinical Investigation Publishes Data Demonstrating Enhanced Antitumor Efficacy of Second Generation DeCIDe™ Technology
- Clinical Responses Demonstrated in Metastatic Castrate Resistant Prostate Cancer Patients Treated with BPX-101 Cancer Vaccine
- Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
- Bellicum Pharmaceuticals Announces World Renowned Clinical Advisory Board Appointments
- Systemic and Antigen-Specific Immune Responses in Patients Treated with Cancer Vaccine BPX-101 Correlate with Clinical Response
- Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
- Bellicum Pharmaceuticals Announces Initiation of Phase I-II Clinical Trial of Novel Vaccine for Patients with Advanced Prostate Cancer
- Bellicum Pharmaceuticals Announces $3.75 Million in Financing
- Bellicum Pharmaceuticals Announces Commercial Licensing of Ariad's Argent™ Cell-Signaling Regulation Technology for Development of New Cancer Therapies